Efficacy and safety of Kang’ai injection adjunct with TP chemotherapy for the treatment of non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

摘要

Lung cancer has become one of the most common and frequent malignant tumors. Non-small cell lung cancer accounts for about 80% of all lung cancers, and about 75% of patients are in the advanced stage when they are discovered. Chemotherapy occupies an important position in the treatment of non-small cell lung cancer, but while chemotherapy brings curative effects, there are serious side effects. Therefore, looking for a drug that can enhance the efficacy of chemotherapy and reduce the side effects of chemotherapy is currently the treatment of lung cancer. One of the research hotspots. Traditional Chinese medicine shows unique advantages in the treatment of lung cancer. Combined with chemotherapy can effectively reduce the side effects of patients, improve the quality of life, and prolong survival. Background: Combination therapy with traditional Chinese medicine and chemotherapy was proposed as a therapeutic strategy for non-small cell lung cancer patients. Therefore, we performed a systematic review and meta-analysis of randomized controlled trials to assess effects of this combination therapy on non-small cell lung cancer. To evaluate the efficacy and safety of the Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy in the treatment of non-small cell lung cancer. Methods: A randomized controlled study of the Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy in the databases of China National Knowledge Infrastructure Database, WanFang Database, VIP Database, Sino-Med Database, PUBMED, EMBASE and Cochrane library was searched by computer. The literatures published from the database establishment to July 1, 2020 were included in the search scope. After 2 evaluators independently evaluated and cross checked the quality of the study, Revman 5.3 was used to meta analyze the clinical effect of the Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy on patients with non-small cell lung cancer. Results: A total of 1,370 lung cancer patients were included in 20 RCTs. The results of meta-analysis showed that there were significant differences between the 2 groups in clinical efficacy (RR = 1.32, 95% CI (1.20, 1.44)), quality of life (RR = 1.44, 95% CI (1.32, 1.57)), immune function (MD = 0.53, 95% CI (0.23–0.83)), adverse reactions (RR = 0.49, 95% CI (0.41, 0.58)). Conclusion: The Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy is effective and safe in the treatment of non-small cell lung cancer, and has great prospects for further development. However, the quality of evidence was very low-to-moderate. Considering the poor quality of evidence, we are not very confident in the results. We look forward to more research and update results in the future and improve the evidence quality.